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and adalimumab (Subcutaneous). The objective of this study was to compare the 
dispensation channel of anti-TNFs used in IBD across European (EU) top 5 coun-
tries. Methods: We analyzed dispensation conditions using IMS data from 2011 
and official local official websites, France (Haute Autorité de Santé and Health insur-
ance drugs database), Italy (Agenzia Italiana del Farmaco), Spain (Ministerio de 
Sanidad Servicios Sociales e Igualdad), Germany (Gemeinsamer Bundesausschuss), 
United Kingdom (Department of Health). Results: In UK, Spain, Italy, both inflixi-
mab and adalimumab dispensation were restricted to hospital channel. In Germany, 
both infliximab and adalimumab can either be dispensed through retail and hos-
pital channels. In France, adalimumab was available either in hospital and retail 
channels under exceptional status, and infliximab was dispensed through hospital 
channels only. The differences across countries could not be related to products 
labels as they are all approved under European Medicines Agency (EMA) centralized 
procedure. ConClusions: It is unlikely that the gaps observed are only related to 
differences in health care services organization but rather budget constraint like 
in UK, Italy and Spain. In Germany and France, the two leading EU pharmaceuticals 
markets this is not yet the case. Hospital dispensation channel of biologics and 
biosimilars is a new way to generate savings mainly through tenders.
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PaedIatrIc GastroenterItIs: dIsease Burden, cost and Loss of 
ProductIvIty of MaLaysIan and vIetnaMese Parents
Azmi S.1, Reginald P.2
1Veras Research, Petaling Jaya, Malaysia, 2Azmi Burhani Consulting, Petaling Jaya, Malaysia
objeCtives: The cost of paediatric gastroenteritis is poorly documented in Asia. 
This analysis reports findings of a survey on disease burden, cost and productivity 
loss caused by paediatric gastroenteritis in Malaysia and Viet Nam. Methods: A 
survey was conducted between August 2012 and April 2013 targeting respondents 
in public spaces in Hanoi and Bac Giang, Viet Nam and Klang Valley, Malaysia. The 
surveys were self-administered and collected information on demographics, disease 
burden, cost and productivity loss. Descriptive analysis was conducted to report the 
overall findings using STATA SE 11.2. Results: Survey questionnaires were com-
pleted by 245 and 307 respondents from Malaysia and Viet Nam, respectively. Over 
90% of the respondents were parents of children below 10. Overall, 69% reported 
that their children experienced gastroenteritis requiring physician visits and 28% 
reported episodes requiring hospital admissions. Differences were noted in the 
treatment seeking patterns between the two countries. These differences influenced 
cost and productivity loss to the families of affected children. In Malaysia, a large 
proportion of parents (41.2%) reported hospitalisation cost to be more than USD 350 
whereas in Viet Nam, a majority (74.6%) reported hospitalisation cost less than USD 
34. Among these, 52.9% and 30.5% of Malaysian and Vietnamese parents paid out-of-
pocket for hospital admission, respectively. The majority reported days off work of 2 
to 5 days, however more parents in Viet Nam (23.7%) required greater than 6 days off 
work to care for their affected child compared to Malaysia (3.9%). ConClusions: 
Gastroenteritis has an impact on cost and productivity loss to parents of affected 
children in Malaysia and Viet Nam. However, there were several differences noted 
likely due to differences in GDP, health system and cultural factors.
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InfLaMMatory BoweL dIseases In ItaLy: IncIdence trends and 
PatIents’ characterIstIcs
Fornari C.1, Madotto F.1, Fiorino G.2, Ardizzone S.2, Bortoli A.2, Caprioli F.2, Cestari R.2,  
Conti S.1, Cortelezzi C.2, Mantovani L.G.3, Massari A.2, Meucci G.2, Ravelli P.2, Vecchi M.2, 
Danese S.2, Cesana G.1
1University of Milano - Bicocca, Monza, Italy, 2EPICO MICI LOMBARDIA Project, Milano, Italy, 
3Federico II University of Naples, Naples, Italy
objeCtives: To assess the impact of inflammatory bowel diseases (IBD) in the 
Italian general population: incidence and time trends from 2003 to 2009, as well 
as population characteristics. Methods: A retrospective observational study was 
conducted in Lombardy, an Italian region with about 10 million of inhabitants, using 
health care administrative databases of the national health care system (HS) which 
provides universal coverage. The main administrative databases were integrated in 
a data warehouse called DENALI using probabilistic record linkage. New cases of 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) were identified in the adult popu-
lation between January 1, 2003 and December 31, 2009. Annual age-standardized 
incidence rates were computed separately for CD and UC using the population 
living in Lombardy at 2001 census. Moreover we evaluated patients’ baseline main 
characteristics, coexisting chronic conditions and survival at December 31, 2009.  
Results: The annual incidence rate per 100,000 person-years of IBD was 15.6 (95%CI 
15.2-15.9); UC and CD incidences were 9.7 (9.4-10.0) and 5.9 (5.7-6.1) respectively. 
Incidence rates of both diseases were higher in men than in women. CD incidence 
was highest in subjects aged 20-24 (9.2, 95%CI 8.1-10.2) and decreased with age, 
while UC incidence was stable in the 20-65 year-old population. No time trends in 
UC and CD incidences were observed from 2003 to 2009, both in the whole study 
population and in gender and age-specific subgroups. The mean age at CD diag-
nosis was 44 years (±16.6 sd), which was lower than that at UC diagnosis (46 ± 16.6, 
p< 0.0001). During a mean follow-up time of 3.4 years (± 2.0) 2.2% of IBD patients 
died. ConClusions: Our study provides updated estimates on current epidemiol-
ogy of IBD in Italy. IBD incidence in Lombardy is lower than in northern Europe and 
the data confirm that UC incidence is higher than that of CD.
sensory systeMs dIsorders – clinical outcomes studies
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IndIrect coMParIson of the effect of BIoLoGIcs In PatIents wIth 
PsorIasIs; a Meta-anaLysIs of randoMIzed, douBLe BLInd cLInIcaL 
trIaLs In BayesIan fraMework
Brodszky V., Mo M., Gulacsi L., Baji P., Balogh O., Péntek M.
Corvinus University of Budapest, Budapest, Hungary
examining aminosalicylates (n= 23), corticosteroids (n= 10), immunosuppressants 
(n= 15), biologics (n= 16) and kinase inhibitors (n= 1). Baseline patient characteristics, 
study design and outcomes were extracted, including: adverse events (AE) (reported 
in n= 24 studies), serious AE (n= 25), deaths (n= 23), clinical remission (n= 49), clini-
cal response (n= 33) and mucosal healing (n= 11). Eleven different disease activity 
scales and four different endoscopic scales were used. The mean age of included 
patients ranged from 27 to 51, and the percentage of males from 28.6% to 87.5%. Due 
to large differences and different scales used for reporting efficacy it is not feasible 
to report the range across different scales. Safety endpoints were also reported 
inconsistently. The results per outcome are presented in a narrative way per treat-
ment class. ConClusions: A comprehensive SLR performed which identified 65 
RCT reporting on the efficacy and safety of pharmacological treatments in moderate 
to severe UC patients. Differences in patient population, disease severity, disease 
activity scales and trial duration are explored and presented.
PGI47
how the PrIcInG strateGy of 2nd GeneratIon hcv dIrect antIvIraL 
aGents can affect the nuMBer of treated PatIents In ItaLy and the 
natIonaL druG BudGet
Lanati E.P.1, Lidonnici D.1, Cammà C.2
1MA Provider Srl, Milan, Italy, 2University of Palermo, Palermo, Italy
objeCtives: To assess the impact of new HCV drugs pricing strategy on the number 
of potential treated/cured patients and on the Italian Healthcare Service budget, 
using a simplistic model to design different scenarios for second generation direct 
antiviral agents (DAAs). Methods: We calculated the HCV drugs budget and the 
number of patients for setting a base case by summing a) AIFA values for HCV 
dual therapy drugs to assess the number of patients currently treated; b) triple 
therapy number of patients estimated from AIFA budget (210.000.000€ in total). 
We performed budget scenarios on two variables: 1) pricing strategy of more effec-
tive DAAs; 2) total HCV drugs budget. We calculated the number of treated and 
responder patients, considering only genotype 1 HCV to maintain a comparability 
between base case and future scenarios with new DAAs. Results: The number of 
patients to be cured with stable budget vs base case are: 1) 9.000 (+56% vs. base case) 
with parity price vs. triple therapy; 2) 7.500 (+30% vs. base case) in case of a 20% 
premium price that would allow 8.300 patients to be treated. Assuming to double 
the allocated budget from payers (420.000.000€ ) and to reduce the new DAAs price 
by a 20%, 25.000 patients will be treated and 22.500 (+291% vs. base case) will be 
cured. ConClusions: This simplified analysis shows that more effective drugs can 
significantly increase the number of patients who could be treated and cured. In 
order to support these results, efforts from both payers (higher budget) and pharma 
companies (lower prices) are needed.
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exPLaInInG the Increased heaLth care exPendItures aMonG 
IndIvIduaLs wIth co-occurrInG chronIc oBstructIve PuLMonary 
dIsease and GastroesoPhaGeaL refLux dIsease: a cost-
decoMPosItIon anaLysIs
Ajmera M.R.1, Raval A.D.1, Shen C.2, Sambamoorthi U.3
1West Virginia University, Morgantown, WV, USA, 2The University of Texas MD Anderson Cancer 
Center, Houston, TX, USA, 3West Virginia University School of Pharmacy, Morgantown, WV, USA
objeCtives: The objective of this study is to examine health care expenditures asso-
ciated with Gastro-esophageal Reflux Disease (GERD) among elderly with Chronic 
Obstructive Pulmonary Disease (COPD) and understand the explanatory factors 
associated with incremental expenditures associated with (GERD). Methods: The 
study utilized retrospective cross-sectional design. Data were extracted from multiple 
years (2006-2009) of the Medicare Current Beneficiaries Survey (MCBS). The analytical 
sample consisted of community dwelling elderly individuals with COPD (n = 3,821) 
identified using appropriate International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes. The key independent variable was defined 
as presence or absence of GERD. T-tests and ordinary least squares regressions (OLS) 
on log-transformed total health care expenditures were performed to analyze the 
association between health care expenditures with GERD among individuals with 
COPD. Blinder-Oaxaca decomposition analysis was performed to estimate contribu-
tion of factors towards explaining the excess health care expenditures. Results: 
Among elderly individuals with COPD, the annual average health care expenditures 
were higher for those with GERD ($36,793 ± $1,387) as compared to those without 
GERD ($24,722 ± $800). Individuals with GERD had poorer health status, low physi-
cal activity profile, and higher rates of obesity. Furthermore, the rates of depression 
and anxiety were significantly higher among individuals with GERD compared to 
those without GERD. A decomposition technique revealed that nearly 30.9% of the 
incremental health care spending associated with GERD was due to the differences in 
characteristics such as Charlson’s comorbitity score (17.5%), perceived health status 
(7.13%) and depression (5.85%). ConClusions: Our findings highlight the burden 
of comorbid conditions among those with COPD and GERD. This study reinforces the 
need to modify the care-delivery model from single-disease care approach to inte-
grated/ multiple diseases care approach to manage the complex comorbid diseases, 
which may ultimately reduce the excess health care expenditures.
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dIsPensatIon channeLs of antI-tnfs In InfLaMMatory BoweL dIsease
Thivolet M.1, Rémuzat C.2, Kornfeld A.1, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical France, Paris, France, 3University Claude 
Bernard Lyon 1, Lyon, France
objeCtives: In The Netherlands, the funding for some high cost drugs and particu-
larly biologics was transferred in 2012 to hospital pharmacy dispensation channel. A 
European study forecast (2012-2016) shown hospital dispensation as a very effective 
policy to reduce budget impact of branded biologics and increase savings related 
to biosimilars. Two biologics (anti-TNFs) are indicated for Inflammatory Bowel 
Disease (IBD) in EU with different mode of administration: infliximab (Intravenous) 
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versus those with associated MH. This analysis establishes the representativeness 
of the MIVI-TRUST patient population in the context of clinical practice.
Pss4
atoPIc derMatItIs: evaLuatIon of 2 dIfferent druG reLated 
ManaGeMents
Taieb C.
CREES PFSA, Paris, France
objeCtives: Atopic Dermatitis (AD) is a chronic relapsing skin condition and one 
of the most common skin diseases worldwide. Nowadays, the prevalence of AD is 
estimated to be between 5%-and-30% in children. AD onset is commonly before 
5years old in children. Therapeutic treatments include topical corticosteroids (CS) 
and long-term emollients as first-line therapy, followed by topical calcineurin inhibi-
tors. Emollients represent one of the cornerstones of treatments for patients with 
AD. The aims of this study were to compare the drug related management and 
the drug related costs between children with AD treated by at least an emollient 
(composed-of-Glycerol [15 gr], Vaseline [8 gr] and liquid-paraffin [2gr] per 100 gr) 
and children not treated by emollient. Methods: This was a retrospective analysis 
of data extracted from the “Disease Analyzer™” database, including anonymized 
data from medical files of the patients seen by a representative sample of FrenchGP. 
Children with AD diagnosed before 1 year old were tracked for 12-months after the 
date of diagnosis. Only children monitored at least 1 year after the diagnosis were 
included in the analysis. Costs of AD treatments were calculated from a societal 
perspective. Results: 49 children with AD were treated by the emollient (group 1) 
and 59 were not (group 2). 59.2% of children of group 1 were treated by CS vs 72.9% in 
group 2; the same trend was found for the prescription of antiseptic (24.5%-vs-27.1%) 
and antibiotic (10.2%-vs-13.6%). On the contrary, healing was more prescribed in the 
emollient group (32.7%-vs-25.4%). Average annual cost of prescribed dermatological 
drugs was estimated to be 139.8 € in the emollient group and 146.4 € in the other 
group. ConClusions: These preliminary results suggest that CS, which may have 
negative effects (skin fragility, infection, addiction and impact on growth), are less 
prescribed in the emollient group. Studies considering larger samples are warranted 
to confirm this trend.
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BaseLIne PatIent, ocuLar features and ManaGeMent of a PatIent 
PoPuLatIon dIaGnosed wIth vItreoMacuLar tractIon: an 
oBservatIonaL study In fLanders
Lescrauwaet B.1, Spaepen E.2, Vriens I.3, Stalmans P.3
1Xintera Consulting, Leuven, Belgium, 2SBD Analytics BVBA/SPRL, Bekkevoort, Belgium, 
3Universitaire Ziekenhuizen Leuven, Leuven, Belgium
objeCtives: Limited data is published on baseline characteristics of patients diag-
nosed with vitreomacular traction (VMT) or different macular hole (MH) stages. Aim 
of our study was to describe the baseline patient and ocular characteristics, and 
the management of patients diagnosed with diseases of the vitreomacular inter-
face. Methods: This was an observational study with retrospective design. The study 
sample included patients from a large tertiary care ophthalmology center in Flanders, 
who had at least 1 outpatient visit at the study center between July 2009 and May 
2013. Patients presented with or without visual symptoms and were examined using 
optical coherence tomography (OCT) in both eyes. Patients diagnosed with other 
retinal diseases were excluded from this study. This analysis reports on the VMT 
cohort only. Results: The study sample included a total of 509 patients of which 
156 patients (191 eyes) presented with VMT. Mean (SD) age was 72.8 (9.8); 59% were 
female. Majority (73%) was referred by an ophthalmologist for symptoms of general 
vision loss (60%) and/or metamorphopsia (23%). Mean follow-up was 1.64 years. Eyes 
in which a vitrectomy was performed (n= 41) presented with worse visual acuity 
(VA) compared with eyes managed through observation (0.43 versus 0.55; p= 0.029). 
However, VA in fellow eye was significantly better in eyes managed with vitrectomy 
(0.7 versus 0.56, p= 0.039). Metamorphopsia (61% versus 37%, p= 0.005) and concomi-
tant ERM (20% versus 9%, p= 0.049) were significantly more prevalent in eyes man-
aged through vitrectomy compared with observation. ConClusions: In a real-life 
population, visiting the outpatient clinic of a large tertiary care ophthalmology center, 
31% of patients presented with VMT. Patients were predominantly managed though 
observation. Worse visual acuity of fellow eye, and presence of metamorphopsia or 
ERM were significantly associated with occurrence of vitrectomy.
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chILdren wIth atoPIc derMatItIs: MonItorInG a french cohort over 
a nIne-year PerIod
Taieb C.
CREES PFSA, Paris, France
objeCtives: To assess the diseases associated with AD or that take over during 
the years following the diagnosis of the infant and to calculate the annual cost of 
treating these children. Methods: The cohort includes infants with AD who have 
undergone consultation with their general practitioners between the beginning of 
2000 to the end of 2003. The data gathered through the IMS database was entered by 
general practitioners, enabling tracking of patients. The tracking period was started 
after diagnosis. Only infants who were monitored for a minimum of one-year were 
included. A control group comprising infants without AD and who were monitored 
for at least a year was created. Results: A total of 723 infants who met the criteria 
outlined were identified. In the first year following their birth, infants with AD had 
significantly more concomitant disorders, particularly respiratory disorders (85% 
vs. 76%), and asthma (8.9% vs 4.6%) or other types of dermatosis (46.9% vs. 28.2%) 
among others. During the nine-years of monitoring, the children of the AD cohort 
consumed more dermatological products than the children of the control-group did 
in terms of emollients or topical corticosteroids. As well, the AD group consumed 
more antiseptic products than the control group did in the first year (27.6% vs 14%). 
Children with AD were observed to consume more anti-asthma drugs, with a peak 
occurring at age 4. ConClusions: From an epidemiological perspective, this study 
objeCtives: The main aims of this systematic review were to identify all relevant 
literature on clinical efficacy for biological medications in patients with psoriasis 
and to conduct an up-to-date meta-analysis. Methods: The following compara-
tors were considered for this analysis: adalimumab, etanercept, infliximab, and 
ustekinumab. A MEDLINE search was conducted until March 2013. The Cochrane 
Highly Sensitive Search Strategy was applied to identify randomized controlled 
publications and was combined with ‘psoriasis’ MeSH terms and drug names. 
Randomized, controlled, clinical trials with adults with moderate-to-severe pso-
riasis where the full paper can be obtained were included. Evidences were com-
bined in a mixed treatment comparisons in a Bayesian framework. Efficacy was 
measured by the 75% and 90% improvement of Psoriasis Area Severity Index (PASI) 
at three months were analysed. Results: Nineteen trials were included in this 
indirect comparison; treatment arms with off-label dosages were excluded. Each 
biologic showed significantly more favourable effect than placebo with respect to 
any level of PASI response. Significantly more patients on infliximab treatment 
met PASI75 endpoint than on etanercept, adalimumab or ustekinumab, combined 
odds ratios (95% confidence intervals) were 5.34 (2.29-12.50), 7.49 (3.31-16.92) and 
3.64 (1.62-8.20) respectively. Similarly, significantly more patients on infliximab 
treatment met PASI90 endpoint than on adalimumab or etanercept, odds ratios 
were 6.12 (1.07-34.86) and 7.78 (1.02-59.01). No significant differences in terms of 
PASI75 and PASI90 improvements were observed between adalimumab, etanercept 
or ustekinumab. ConClusions: All biologics demonstrated statistically significant 
improvements compared to placebo. This review also showed that infliximab was 
significantly more efficacious than other biologics.
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coMParatIve effectIveness of Peak and trouGh effects of 
BIMatoProst 0.03%/tIMoLoL 0.5% PreservatIve-free fIxed coMBInatIon 
for the treatMent of oPen-anGLe GLaucoMa and ocuLar 
hyPertensIon
Harvey B.1, Stradwick S.1, Brereton N.J.1, Shergill S.2, Wong W.3
1BresMed, Sheffield, UK, 2Allergan Ltd., Marlow, UK, 3Allergan Inc., Irvine, CA, USA
objeCtives: To evaluate the comparative effectiveness of bimatoprost 0.03%/
timolol (BTFC) 0.5% preservative-free (PF) fixed combination solution in single 
dose vials (BTFC PF) for the treatment of glaucoma/ocular hypertension (OHT) 
compared to alternative combination therapies accounting for fluctuations in 
intraocular pressure (IOP). Methods: A systematic review was conducted to iden-
tify randomised controlled trials investigating efficacy of combination therapies 
for the treatment of glaucoma/OHT; where efficacy is defined as IOP change from 
baseline. Maximum and minimum changes in IOP were used as a representa-
tion of peak and trough effects of medication. Prostaglandin/prostamide analog 
and timolol monotherapy trials were also included as key connectors. A Bayesian 
mixed treatment comparison (MTC) analysis was used to synthesise the resulting 
evidence base. Supportive probability of best and rankogram summary analysis 
were used to position treatments within the network based on efficacy. Results: 
A total of 136 studies met the pre-determined MTC inclusion criteria in total; 
representing 24 unique treatment arms. BTFC PF was numerically superior to all 
treatments (monotherapies and combination therapies; preserved and PF thera-
pies) in lowering IOP efficacy in both peak and trough analyses. This superiority 
was statistically significant (p< 0.05) for 18/23 comparisons in both analyses. Lack 
of evidence is the likely reason for non-significance in remaining comparisons. The 
probability of the BTFC formulations (preserved or PF) being the best treatments 
in the network was 0.94 (94% chance) in the peak analysis and 0.90 (90% chance) 
in the trough analysis; BTFC PF specifically had a 57% chance in the peak analysis 
and 62% chance in the trough analysis. No other treatments had > 6% chance. 
Overall ranking of BTFC PF and BTFC preserved in terms of IOP-lowering efficacy 
was 1st and 2nd respectively. ConClusions: BTFC PF showed the greatest clinical 
efficacy of any combination- or mono-therapy in reducing IOP from baseline in 
patients with glaucoma and/or OHT.
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BaseLIne characterIstIcs and vItreoretInaL Interface features In 
PatIents wIth vItreoMacuLar tractIon and MacuLar hoLe froM the 
MIvI-trust cLInIcaL ProGraM
Lescrauwaet B.1, Koshy Z.2, Labourette A.3, Duchateau L.4
1Xintera Consulting, Leuven, Belgium, 2University Hospital Ayr, Ayr, UK, 34Clinics, Paris, France, 
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objeCtives: There is limited published evidence on demographic and vitreoretinal 
interface (VRI) characteristics of patients with vitreomacular traction (VMT), includ-
ing when associated with macular hole (VMT+MH). Establishing insights into the 
characteristics of untreated VMT patients may contribute to a better understanding 
of the burden of VMT disease. The objective of our analysis is to describe baseline 
patient characteristics and VRI features in patients with persistent VMT included in 
the phase 3 ocriplasmin studies. This analysis reports on VMT patients without MH 
(VMT) and VMT patients with MH (VMT+MH). Methods: Two randomized, double-
masked, placebo-controlled trials designed to determine efficacy and safety of ocri-
plasmin for the treatment of VMT comprising of 652 patients (VMT n= 499; VMT+MH 
n= 153). Baseline characteristics included patient demographics (age, gender); eye-
disorder characteristics (time since diagnosis, visual acuity (VA) in study eye (SE); VA 
in non-study eye (NSE), presence of pseudophakia and/or ERM; VRI features (focal 
adhesion ≤ 1500 microns; min-max MH width), VFQ-25 composite score. Results: 
Baseline characteristics for VMT vs. VMT+MH patients were respectively: 72.6 ver-
sus 68.7 years; 62.7% versus 75.8% female. Time since diagnosis: 268 days versus 
62 days; VA: SE 66.8 versus 55.9, NSE 73.5 versus 77.8. Pseudophakes: 38.7% ver-
sus 20.9%, concomitant ERM: 46.3 % versus 15.8%. The majority of VMT patients 
presented with focal adhesion ≤ 1500 microns (69%) while VMT+MH patients pre-
sented with a min-max hole width of 272.7 microns. VFQ-25 composite score: 78.0 
vs. 80.3. ConClusions: Baseline characteristics of the MIVI-TRUST ocriplasmin 
patient population show differentiations between patients with persistent VMT 
